[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model

Abstract
The aim of this investigation was to quantitatively compare the novel positron emission tomography (PET) hypoxia marker 2-(2-nitroimidazol-1-yl)-N-(3[18F],3,3-trifluoropropyl)acetamide ([18F]EF3) with the reference hypoxia tracer [18F]fluoromisonidazole ([18F]FMISO).